Search
Aflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigational[L47915] All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrates and exhibit some degree of chain heterogeneity, including … [L47966,L47971] The intravitreal formulation, under the brand name EYELEA, was approved by the FDA for the treatment of retinopathy of prematurity in preterm infants in February 2023 and for the treatment
Products: ZALTRAP CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML, Zaltrap 25mg/ml Concentrate for Solution for InfusionBouteloua gracilis pollen
go.drugbank.com/drugs/DB10715ApprovedBouteloua gracilis pollen is the pollen of the Bouteloua gracilis plant. Bouteloua gracilis pollen is mainly used in allergenic testing.
Categories: Grass Pollen Allergen ExtractsSynonyms: grama grass pollen extractDL-alpha tocopheryl acetate
go.drugbank.com/drugs/DB14477ApprovedSynonyms: all-rac-alfa-tocopheryl acetate, all-rac-alpha-tocopheryl acetateMixtures: Fizz Multivitamins for Kids W C Loz, Poly Vi Flor Chewable TabInfliximab
go.drugbank.com/drugs/DB00065ApprovedInvestigationalThey are approved for all eligible indications of the reference product. Inflectra, a first biosimilar drug product, was approved in 2016. … It is indicated for the treatment of various inflammatory disorders such as adult or pediatric Chron's disease, adult or pediatric ulcerative colitis, rheumatoid arthritis in combination with methotrexate
Categories: Biologics for Rheumatoid Arthritis TreatmentProducts: POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIAL, REMICADE POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 mg/vialKoeleria macrantha pollen
go.drugbank.com/drugs/DB10949ApprovedKoeleria macrantha pollen is the pollen of the Koeleria macrantha plant. Koeleria macrantha pollen is mainly used in allergenic testing.
Synonyms: Koelers grass pollen extract, Standardized june grass pollenCategories: Grass Pollen Allergen ExtractsInotuzumab ozogamicin
go.drugbank.com/drugs/DB05889ApprovedInvestigational[A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Products: BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIALAntihemophilic factor human
go.drugbank.com/drugs/DB13192ApprovedInvestigationalAntihemophilic factor human is approved by the Food and Drug Administration for use in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes [FDA Label]. … Replacement of Factor VIII is essential for the treatment of Hemophilia A, which is caused by mutations in the Factor VIII gene, leading to a functional deficiency or complete loss of protein.
Mixtures: Haemate P Powder and solvent for solution for injection or infusion, Haemate P 1000IU Powder and solvent for solution for injection or infusionProducts: BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 500IU/VIALPegaspargase
go.drugbank.com/drugs/DB00059ApprovedInvestigationalleukemia (ALL). … [A255912,A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927]
Categories: Compounds used in a research, industrial, or household settingProducts: ONCASPAR POWDER FOR SOLUTION FOR INJECTION/INFUSION 750 U/ML, Oncaspar 750 U/ml powder for solution for injection/infusionLevosimendan
go.drugbank.com/drugs/DB00922ApprovedInvestigationalWithdrawnLevosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triph...
Categories: Compounds used in a research, industrial, or household settingProducts: SIMDAX 2.5 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION, Simdax 2.5 mg/ml concentrate for solution for infusion.Ramucirumab
go.drugbank.com/drugs/DB05578ApprovedInvestigationalRamucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing … In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it.
Products: CYRAMZA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML, CYRAMZA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML